Elicera Therapeutics
Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Once granted, the patent can be kept in force until 2036.
"iTANK is one of our key assets and together with the recently approved European patent we now have strong protection for the technology. China is one of the most important markets in the CAR T-cell field so this is very significant for us," says Jamal El-Mosleh , CEO of Elicera Therapeutics.
| Datum | 2023-09-08, kl 10:05 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.